Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto

Quovadis Associazione

Status: Completed

Conditions: COVID-19; Hypercoagulability

Treatments: Drug: Low Molecular Weight Heparin

Study type: Observational

Funder types: Other

Identifiers

NCT04393805

HETHICO

Details and patient eligibility

About

The HETHICO study aims to collect retrospectively documented clinical information on patients hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings, medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or in preventing thrombotic complications related to hospitalization from COVID-19.

Full description

The HETHICO study aims to collect retrospectively documented clinical information on patients hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings, medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or in preventing thrombotic complications related to hospitalization from COVID-19.

Furthermore, the possible association between the observed clinical evolution and the type of antithrombotic prophylaxis performed (class of drug and dose intensity) will be assessed in a large cohort of patients hospitalized in the various participating hospitals in the Veneto region and observed with follow-up. in the short term, gathering information on:

Clinical outcomes, Survival, Concomitant pathologies, Adverse events of anticoagulant drugs, Interactions with other concomitant drugs, and Risk factors.

The collected data, suitably anonymized, will be used to produce scientific works, the standardization of care paths, and the planning of targeted training events.

Enrollment: 744 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• proved SARS-COVID-2 infection

Exclusion criteria

• none

Trial design

744 participants in 2 patient groups

MED-Cohort

Description:

Patients hospitalized for SARS-COVID-2 infection in a medical ward

Treatment:

Drug: Low Molecular Weight Heparin

ICU-Cohort

Description:

Patients hospitalized for SARS-COVID-2 infection in a sub-intensive or intensive care unit

Treatment:

Drug: Low Molecular Weight Heparin